Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
Companies Commented On
From 1982ľ1990, Michael Berry served as a professor of investments at the Colgate Darden Graduate School of Business Administration at the University of Virginia, during which time he published a book, Managing Investments: A Case Approach. He was the Wheat First Professor of Investments at James Madison University. He has managed small- and mid-cap value portfolios for Heartland Advisors and Kemper Scudder. His publication, Morning Notes, analyzes emerging geopolitical, technological and economic trends. He travels the world with his son, Chris, looking for discovery opportunities for his readers.
Spot Tenbagger Discovery Potential in Biotech: Michael Berry (8/22/13) How do the best investors detect life science companies with the potential to generate significant wealth? Michael Berry, publisher of Morning Notes, found that traditional growth and value models didn't measure up, so he developed his own "discovery" strategy. He looks at companies that haven't gone public yet. He's not afraid of the penny stock. Find out more about Berry's technique, and about five companies that fit his profit-generating profile, in this interview with The Life Sciences Report.
Gold Has Stood the Test of Time: Michael and Chris Berry (6/13/13) The synergy of temperament and intellect has fostered much success for the father-son team of Michael Berry, editor of Morning Notes, and Chris Berry, founder of House Mountain Partners LLC. In this Father's Day interview, the Berrys reveal what they've learned from each other's investment strategies over the years and why they are still bullish on gold.
Transformative Energy Technologies: Michael and Chris Berry (6/13/13) The synergy of temperament and intellect has fostered much success for the father-son team of Michael Berry, editor of Morning Notes, and Chris Berry, founder of House Mountain Partners LLC. In this Father's Day interview with The Energy Report, the Berrys reveal what they've learned from each other's investment strategies over the years, and mull energy metals and emerging green technologies that could be "compelling investment opportunities." They also reveal that, for all the familial camaraderie, there are energy issues about which they strongly disagree.
"PSTI's ability to vary the cell phenotype for a specific therapy is unique in the regenerative medicine space." (3/6/14) Pluristem Therapeutics Inc. - The Life Sciences Report Interview with George Zavoico Moreá>
"The fact that CGIX was able to get a practiced sales force to take its products to market is a very big deal." (3/5/14) Cancer Genetics Inc. - The Life Sciences Report Interview with Ben Haynor Moreá>
"NEO is in the process of launching next-generation sequencing for the clinical trial market; the deal with Covance sets the stage for the company to go to the next level." (2/27/14) NeoGenomics Laboratories - The Life Sciences Report Interview with Debjit Chattopadhyay Moreá>